Teva Pharmaceuticals (NYSE: TEVA) beat Q2 earnings estimates, but fell short of Street's revenue targets. The drug manufacturer reported adjusted EPS of
Search Results for: Teva
Corteva Inc. (NYSE: CTVA) Q1 2020 Earnings Call Transcript
Corteva Inc. (CTVA) Q1 2020 earnings call dated May 07, 2020 Corporate Participants: Megan Britt -- Investor Relations, Contact James (Jim) C. Collins -- Chief Executive
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q1 2020 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (TEVA) Q1 2020 earnings call dated May 07, 2020 Corporate Participants: Kevin C. Mannix -- Senior Vice President, Investor Relations
Infographic: Teva Pharmaceuticals (TEVA) Q1 2020 earnings results
Teva Pharmaceuticals' (NYSE: TEVA) first quarter 2020 results beat consensus estimates. The drugmaker reported adjusted earnings of $0.76 per share on revenue
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q4 2019 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q4 2019 Earnings Conference Call February 12, 2020 Corporate participants: Kevin C. Mannix -- Senior Vice President, Investor
It’s time to see Teva Pharmaceuticals (TEVA) from a different perspective
Shares of Teva Pharmaceuticals (NYSE: TEVA) fell to a new low this month as markets across the world continued to be battered
Teva Pharmaceutical (TEVA) swings to profit in Q4, beats estimates
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) swung to a profit in the fourth quarter of 2019 from a loss last year, helped
Teva Q3 profit misses estimates, tightens FY19 forecast
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported a wider loss in the third quarter of 2019 as generic competition hurt Copaxone revenue
Teva’s Q2 results beat market expectations
Teva Pharmaceutical Industries (NYSE: TEVA) topped revenue and earnings estimates for the second quarter of 2019, giving shares a lift of 1.4%
Earnings preview: Teva’s struggles might not end in Q2
Teva Pharmaceuticals (NYSE: TEVA) is scheduled to report second quarter 2019 earnings results on Wednesday, August 7, before market open. Analysts expect
Teva Pharma sinks on Q1 revenue miss amid generic competition; earnings beat
Drugmaker Teva Pharmaceutical (NYSE: TEVA) reported a decline in first-quarter adjusted earnings, owing to a 15% fall in revenues as the company
Earnings preview: New product launches in focus as Teva gets ready for Q1 report
Teva Pharmaceutical (NYSE: TEVA) has long endued uncertainties in business even as the generic drug maker continued its efforts to tackle high
Earnings: Teva Pharma shrinks Q4 losses, but revenue falls
Teva Pharma (TEVA) posted its fourth-quarter 2018 before the opening bell on Feb. 13. The generic drugmaker saw revenue slip 16% to $4.56
Earnings Preview: Positive sentiment around Teva
Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report fourth-quarter 2018 earnings results on Wednesday, February 13, before market open. Wall Street
Teva’s shares soar on better-than-expected Q3 results and higher guidance
Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock gain over 6.8% during premarket hours on Thursday after the company surpassed expectations on
Earnings Preview: It’s a mixed bag for Teva Pharma in Q3
Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to post its third-quarter 2018 earnings on Nov 1, before the opening bell. So, what
Teva Pharma receives a booster shot with FDA approval
The US FDA on Thursday approved Teva Pharmaceuticals’ (TEVA) generic version of EpiPen and EpiPen Jr auto-injector for the emergency treatment of
Teva Pharmaceuticals shares take a tumble despite earnings beat
Teva Pharmaceutical Industries Ltd. (TEVA) beat market estimates on adjusted EPS for Q2 2018 while revenues came in line with expectations. Despite
US generic drug market throttles Teva Pharmaceuticals as revenue slips
Teva Pharmaceuticals Industries Ltd. (TEVA) reported a decrease of 10% in revenues to $5.1 billion for the first quarter of 2018 compared
Amarin (AMRN) stock to remain within a tight range until the end of Vascepa litigation
The patent war between Amarin (NASDAQ: AMRN) and the generic companies for cardiovascular drug Vascepa continues to be a headwind for Amarin.
Deckers Outdoor Corp (NYSE: DECK) Q4 2020 Earnings Call Transcript
Deckers Outdoor Corp (DECK) Q4 2020 earnings call dated May 21, 2020 Corporate Participants: Erinn Kohler -- Vice President of Investor Relations & Corporate